$61.46▴ 2.59%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$3.25cash per $1 profit
Strong
It turns every reported profit-dollar into real cash, and then some.
Valuation
96th pctvs its own history
Rich
Its valuation sits in the richer end of its own recent range.
Revenue growth
+2.8%year over year
Watch
Revenue growth has flattened.
Leverage
Lowdebt to assets
Healthy
A modest, well-covered debt load.
More coming: dilution / share-count creep.
Fair value
Fairly valued
Trading right around our fair-value range
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
BioMarin Pharmaceutical Inc. turns 325¢ of every reported profit-dollar into real cash. Revenue growth has flattened. Its valuation sits in the richer end of its own recent range. A modest, well-covered debt load.
Key numbers
Valuation
EPS (TTM)$1.37
TTM (trailing 12 months, through fiscal Q1 FY2026)
Profitability
Net margin8.3%
TTM (trailing 12 months, through fiscal Q1 FY2026)
Size
Revenue (TTM)$3.24B
TTM (trailing 12 months, through fiscal Q1 FY2026)
Recent news
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.